Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[midastouch017]

Kitov to Host Business Update Call on Monday, January 23, 2017

TEL AVIV, Israel, January 17, 2017 /PRNewswire/ --

Management to Discuss Acquisition of Oncology Company, TyrNovo, Ltd.

KIT-302 Development On Track For An NDA Submission to the FDA in Q1 2017

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced that it will host a business update call on Monday, January 23rd at 8:30am Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, and to discuss the development plans for KIT-302, which is currently on-track for an NDA submission during the first quarter of 2017.
Kitov previously announced its recent acquisition of a majority stake in TyrNovo Ltd., a privately held developer of novel small molecules in the -oncology therapeutic field, on January 12, 2017. Members of management scheduled to speak on the call include Dr. Paul Waymack, MD, Sc.D., Founder, Chairman of the Board and Chief Medical Officer, Isaac Israel, Chief Executive Officer, Dr. Gil Ben-Menachem, Ph.D. MBA, VP Business Development, and Simcha Rock, CPA, MBA, Chief Financial Officer.

Monday, January 23rd@ 8:30am Eastern Time Domestic: 888-600-4861 International: 913-312-0420 Israel: 1 80 925 8350 Passcode: 5906623 Webcast: http://public.viavid.com/index.php?id=122604 Replays, available through February 6th Domestic: 844-512-2921 Int'l: 412-317-6671 Replay PIN: 5906623
About Kitov Pharmaceuticals

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare and research professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov's flagship combination drug, KIT-302, intended to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoint for its Phase III clinical trial. KIT-302's New Drug Application with the U.S. Food and Drug Administration is currently being prepared for submission. Kitov's newest drug NT219, a potential immuno-oncology combination product, is being developed by Kitov's recently acquired subsidiary, TyrNovo Ltd. NT219 is a small molecule that presents a new concept in cancer therapy. In combination with various approved oncology drugs, NT219 demonstrated potent anti-tumor effects and increased survival in various cancer models, including sarcoma, melanoma, pancreatic, lung, ovarian, head & neck, prostate and colon cancers. Its mechanism of action is through the prevention of acquired resistance in tumors and by regression of resistant tumors. By lowering development risk and cost, including via fast-track regulatory approval of novel late-stage and other therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives. For more information on Kitov, the content of which is not part of this press release, please visit http://www.kitovpharma.com.